drug
efzofitimod
Phase 2updated 5mo agoby $ATYR aTYR PHARMA INC
Phase 2community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying efzofitimod
- phase3Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
- phase2Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- phase2Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19
- phase2Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis
News(2)
- August biopharma layoffs impact just over 500, down 90% year over yearLast month, biotech and pharma companies making or planning workforce cuts included three whose reductions will more than halve their workforces. Blueprint Medicines’ layoffs will affect the most e…biospace · 19d ago
- aTyr lays off 60% of workforce to fund 2nd attempt at phase 3 success for lung disease drugSixty per cent of aTyr Pharma’s workforce are heading for the exits as the biotech conserves resources for a second shot at phase 3 success in a type of lung disease.fiercebiotech · 1mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that